1. Home
  2. KLIC vs CRNX Comparison

KLIC vs CRNX Comparison

Compare KLIC & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kulicke and Soffa Industries Inc.

KLIC

Kulicke and Soffa Industries Inc.

HOLD

Current Price

$64.40

Market Cap

3.3B

Sector

Technology

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$33.73

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLIC
CRNX
Founded
1951
2008
Country
Singapore
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.9B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
KLIC
CRNX
Price
$64.40
$33.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$54.67
$74.78
AVG Volume (30 Days)
499.4K
1.1M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
1.27%
N/A
EPS Growth
100.32
N/A
EPS
0.32
N/A
Revenue
$654,081,000.00
$1,039,000.00
Revenue This Year
$45.04
$722.66
Revenue Next Year
$11.95
$183.79
P/E Ratio
$202.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.63
$24.10
52 Week High
$77.50
$57.99

Technical Indicators

Market Signals
Indicator
KLIC
CRNX
Relative Strength Index (RSI) 47.07 29.20
Support Level $61.28 $33.23
Resistance Level $72.90 $37.23
Average True Range (ATR) 2.61 1.62
MACD -0.20 0.13
Stochastic Oscillator 31.30 8.33

Price Performance

Historical Comparison
KLIC
CRNX

About KLIC Kulicke and Soffa Industries Inc.

Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: